A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
← catalyst calendarNCT05735483 · readout ≤ 498 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Enrolling by invitation
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
333estimated
Sites
94
Countries
Argentina, Australia, Brazil +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-09 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Atopic Dermatitis
- Eczema
Interventions
- Drug: Lebrikizumab — also filed as LY3650150
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants Discontinued From Study Treatment due to Adverse Events (AEs)
measured Baseline through Week 52
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed